1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,750 | 10,000 | 07.12. | |
| 9,600 | 10,400 | 05.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11. | MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 14.11. | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 2 | Seeking Alpha | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11. | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | 176 | GlobeNewswire (Europe) | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| 07.11. | MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 | 192 | GlobeNewswire (Europe) | Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune... ► Artikel lesen | |
| 05.11. | MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | 3 | GlobeNewswire (USA) | ||
| 30.10. | MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | 3 | GlobeNewswire (USA) | ||
| 29.09. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09. | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 10 | GlobeNewswire (USA) | ||
| 25.09. | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| 18.09. | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| 15.08. | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 4 | Investing.com | ||
| 14.08. | MiNK Therapeutics GAAP EPS of -$1.06 misses by $0.51 | 4 | Seeking Alpha | ||
| 14.08. | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 191 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.08. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | MiNK Therapeutics: H.C. Wainwright stuft Aktie nach Kursrallye auf "Neutral" herab | 17 | Investing.com Deutsch | ||
| 15.07. | MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright | 2 | Investing.com | ||
| 15.07. | Mink Therapeutics stock tumbles on $50 million stock offering | 5 | Investing.com | ||
| 15.07. | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 15.07. | Nach Kursrallye von über 460 %: MiNK Therapeutics kündigt Kapitalerhöhung über 50 Mio. US-Dollar an | 5 | Investing.com Deutsch |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 49,250 | +1,34 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,235 | +0,38 % | Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics | ||
| NOVOCURE | 10,350 | -0,48 % | Novocure CEO Ashley Cordova Resigns; Frank Leonard Named Replacement | WASHINGTON (dpa-AFX) - NovoCure Ltd. (NVCR), a Swiss medical devices and healthcare company, Monday announced that its chief executive officer, Ashley Cordova has resigned from the company.Frank... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,454 | -0,95 % | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | ||
| MEREO BIOPHARMA | 1,755 | -1,13 % | Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data | ||
| BIOLINERX | 2,545 | -7,12 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| ASSERTIO | 0,770 | -1,84 % | Assertio Holdings, Inc.: Assertio Announces Leadership Transition | Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,190 | +1,55 % | Applied Therapeutics: Herabstufung durch Leerink Partners wegen Liquiditätssorgen | ||
| ROIVANT SCIENCES | 18,230 | +1,19 % | Roivant Sciences: Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) | Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including... ► Artikel lesen | |
| REVOLUTION MEDICINES | 68,50 | 0,00 % | INSIDER-REPORT: Massive Insiderverkäufe bei NVIDIA und Coreweave - wo Insider jetzt aktiv werden | ||
| AKERO THERAPEUTICS | 46,940 | +0,21 % | Akero-Aktionäre stimmen Übernahme durch Novo Nordisk zu | ||
| ARVINAS | 12,785 | +1,87 % | Arvinas Inc.: Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition | ||
| JANUX THERAPEUTICS | 16,510 | +0,67 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| WEREWOLF THERAPEUTICS | 0,950 | -4,65 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,750 | -1,46 % | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,00 % bei einem Aktienkurs von 10,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.